DNA methylation and essential hypertension: A review

Progress in Biochemistry and Biophysics

Volumn 37, Issue 4, 2010, Pages 364-369

  Du, Xia ^a   Yuan, Hong ^a   Xing, Xiao Wei ^a  

^a THE THIRD XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

DNA methylation; Essential hypertension; Gene; Individual treatment; Pathogenesis

Indexed keywords

EID: 77954786772     PISSN: 10003282     EISSN: None     Source Type: Journal    
DOI: 10.3724/SP.J.1206.2009.00689     Document Type: Article

References (41)

1. Tan S X, Li J, Yi H, et al. Prog Biochem Biophys, 2009, 36(6):743-749
2. McCabe M T, Brandes J C, Vertino P M. Cancer DNA methylation: molecular mechanisms and clinical implications. Clin Cancer Res, 2009,15(12):3927-3937
3. Cotton A M, Avila L, Penaherrera M S, et al. Inactive X chromosome-specific reduction in placental DNA methylation. Hum Mol Genet, 2009,18(19):3544-3552
4. Deng T, Kuang Y, Zhang D, et al. Disruption of imprinting and aberrant embryo development in completely inbred embryonic stem cell-derived mice. Dev Growth Differ, 2007,49(7):603-610
5. Gu D F, Reynolds K, Wu X G, et al. Prevalence, awareness, treatment, and control of hypertension in China. Hypertension,2002,40(6):920-927
6. Kelly T N, Gu D F, Chen J, et al. Hypertension subtype and risk of cardiovascular disease in Chinese adults. Circulation, 2008,118(15):1558-1566
7. Bogdarina I, Murphy H C, Burns S P, et al. Investigation of the role of epigenetic modification of the rat glucokinase gene in fetal programming. Life Sci, 2004,74(11):1407-1415
8. Bogdarina I, Welham S, King P J, et al. Epigenetic modification of the renin-angiotensin system in the fetal programming of hypertension. Circ Res, 2007,100(4):520-526
9. Bogdarina I G, King P J, Clark A J. Characterization of the angiotensin (AT1b) receptor promoter and its regulation by glucocorticoids. J Mol Endocrinol, 2009,43(2):73-80
10. Nuyt A M, Szyf M. Developmental programming through epigenetic changes. Circ Res, 2007,100(4):452-455
11. Yuan H, Huang Z J, Xing X W, et al. Inhibitors of DNA methyltransferase and histone deacetylase regulate the expression of β1 -adrenoceptor gene in myocardial cells. Cell Biol Int, 2008,32 (3):S7-S8
12. Draper N, Stewart P M. 11-hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action. J Endocrinol, 2005,186(2):251-271
13. Alikhani-Koopaei R, Fouladkou F, Frey F J, et al. Epigenetic regulation of 11 β-hydroxysteroid dehydrogenase type 2 expression. Clin Invest, 2004,114(8):1146-1157
14. Friso S, Pizzolo F, Choi S W, et al. Epigenetic control of 11 beta-hydroxysteroid dehydrogenase 2 gene promoter is related to human hypertension. Atherosclerosis, 2008,199(2):323-327
15. Wyrwoll C S, Mark P J, Waddell B J. Developmental programming of renal glucocorticoid sensitivity and the renin-angiotensin system. Hypertension, 2007,50(3):579-584
16. Burns S P, Desai M, Cohen R D, et al. Gluconeogenesis, glucose handling, and structural changes in livers of the adult offspring of rats partially deprived of protein during pregnancy and lactation. J Clin Invest, 1997,100(7):1768-1774
17. Funke-Kaiser H, Reichenberger F, Kopke K, et al. Differential binding of transcription factor E2F-2 to the endothelin-converting enzyme-lb promoter affects blood pressure regulation. Hum Mol Genet, 2003,12(4):423-433
18. Funke-Kaiser H, Thomas A, Bremer J, et al. Regulation of the major isoform of human endothelin-converting enzyme-1 by a strong housekeeping promoter modulated by polymorphic microsatellites. J Hypertens, 2003,21(11):2111-2124
19. Lirm U, Cassano P A. Homocysteine and blood pressure in the third national health and nutrition examination survey, 1998-1994. Am J Epidemiol, 2002,156(12):1105-1113
20. Mizrahi E H, Noy S, Sela B A, et al. Further evidence of interrelation between homocysteine and hypertension in stroke patients: a cross-sectional study. Isr Med Assoc J, 2003, 9(15):791-793
21. Steed M M, Tyagi N, Moshal K, et al. Homocysteine and oxidative mechanisms of vascular remodeling. FASEB J, 2007, 21: 897-25 (Meeting Abstract)
22. Ovechkin A V, Tyagi N, Sen U, et al. 3-Deazaadenosine mitigates arterial remodeling and hypertension in hyperhomocysteinemic mice. Am J Physiol Lung Cell Mol Physiol, 2006, 291 (5):L905-L911
23. Virdis A, Ghiadoni L, Cardinal H, et al. Mechanisms responsible for endothelial dysfunction induced by fasting hyperhomocystinemia in normotensive subjects and patients with essential hypertension. J Am Coll Cardiol, 2001,38(4):1106-1115
24. Ingrosso D, Pema A F. Epigenetics in hyperhomocysteinemic states. A special focus on uremia. Biochimica et Biophysica Acta, 2009, 1790(9):892-899
25. Wilson F A, van den Borne J J, Calder A G, et al. Tissue methionine cycle activity and homocysteine metabolism in female rats:impact of dietary methionine and folate plus choline. Am J Physiol Endocrinol Metab, 2009,296(4):e702-e713
26. Kim J M, Hong K, Lee J H, et al. Effect of folate deficiency on placental DNA methylation in hyperhomocysteinemic rats. J Nutr Biochem, 2009,20(3):172-176
27. Kim J M, Hong K, Lee S, et al. Folate supplementation to the hyperhomocysteinemic pregnant rats prevent the alteration of homocysteine metabolism and DNA methylation in the placenta. FASEB J, 2007,21:A345
28. Ingrosso D, Cimmino A, Perna A F, et al. Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinaemia in patients with uraemia. Lancet, 2003,361(9370):1693-1699
29. Castro R, Rivera I, Struys E A, et al. Increased homocysteine and S-adenosylhomocysteine concentrations and DNA hypomethylation in vascular disease. Clin Chem, 2003,49(8):1292-1296
30. Jiang Y D, Zhang J Z, Huang Y, et al. Prog Biochem Biophys,2007,34(5): 479-489
31. Johnson J A, Zineh I, Puckett B J, et al. Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther, 2003,74(1):44-52
32. Evison B J, Bilardi R A, Chiu F C, et al. CpG methylation potentiates pixantrone and doxorubicin-induced DNA damage and is a marker of drug sensitivity. Nucleic Acids Res, 2009, 37(19):6355-6370
33. Zhang Y J, Zhao S L, Tian X Q, et al. Combined inhibition of Dnmt and mTOR signaling inhibits formation and growth of colorectal cancer. Int J Colorectal Dis, 2009,24(6):629-639
34. Zhang Z P, Wu M H, Tang H L, et al. Prog Biochem Biophys, 2009,36(7):904-909
35. Alyaqoub F S, Tao L H, Kramer P M, et al. Prevention of mouse lung tumors and modulation of DNA methylation by combined treatment with budesonide and Rl 15777(Zarnestra MT). Carcinogenesis, 2007,28(1):124-129
36. Koga Y, Kitajima Y, Miyoshi A, et al. The significance of aberrant CHFR methylation for clinical response to microtubule inhibitors in gastric cancer. J Gastroenterol, 2006,41(2):133-139
37. Yanokura M, Banno K, Kawaguchi M, et al. Relationship of aberrant DNA hypermethylation of CHFR with sensitivity to taxanes in endometrial cancer. Oncol Rep, 2007, 17(1):41-48
38. Yuan H, Huang Z J, Yang G P, et al. Effects of polymorphism of the β1-adrenoreceptor and CYP2D6 on the therapeutic effects of metoprolol. J Int Med Res, 2008,36(6):1354-1362
39. Yuan H, Huang Z J, Liu J J, et al. Influence on metoprolol antihypertensive effect of βl-adrenoceptor gene polymorphism and methylated modication. Cell Biol Int, 2008,32(3):S7
40. Zineh I, Beitelshees A L, Gaedigk A, et al. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther, 2004, 76(6):536-544
41. Jiang Q X, Yuan H, Huang Z J. DNA methylation might be the epigenetic molecular mechanism of different antihypertensive efficacy of metoprolol in βl-AR gene-directed therapy. Med Hypotheses, 2009,72(3):364-365